Lung carcinoma cell type unspecified recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lung carcinoma cell type unspecified recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Durvalumab with Thoracic Radiotherapy and Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer After Initial Treatment https://clinicaltrials.eu/trial/study-on-thoracic-radiotherapy-and-durvalumab-for-patients-with-extensive-stage-small-cell-lung-cancer/ Wed, 29 Apr 2026 14:58:02 +0000 https://clinicaltrials.eu/trial/study-on-thoracic-radiotherapy-and-durvalumab-for-patients-with-extensive-stage-small-cell-lung-cancer/ This study focuses on patients with extensive-stage small cell lung cancer who have responded to initial treatment. The research examines the effectiveness of combining chest radiation therapy with a medication called durvalumab (also known as MEDI4736). This medication belongs to a group of drugs called immunotherapy, which helps the body’s immune system fight cancer cells.

The study evaluates how well patients respond to treatment that includes chemotherapy drugs (cisplatin or carboplatin, and etoposide) given together with durvalumab, followed by durvalumab alone while receiving radiation therapy to the chest area. The main goal is to determine how long patients can live without their cancer getting worse after receiving this combination of treatments.

During the study, participants will receive durvalumab through intravenous infusion, which means the medication is given directly into a vein. The maximum daily dose of durvalumab is 1500 milligrams, and treatment may continue for up to 15 months. Throughout the study, doctors will monitor the cancer’s response to treatment and check for any side effects.

]]>